1714 related articles for article (PubMed ID: 8425193)
1. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps.
Ollert MW; Kadlec JV; David K; Petrella EC; Bredehorst R; Vogel CW
J Immunol; 1994 Sep; 153(5):2213-21. PubMed ID: 8051421
[TBL] [Abstract][Full Text] [Related]
3. C3-cleaving membrane proteinase. A new complement regulatory protein of human melanoma cells.
Ollert MW; Frade R; Fiandino A; Panneerselvam M; Petrella EC; Barel M; Pangburn MK; Bredehorst R; Vogel CW
J Immunol; 1990 May; 144(10):3862-7. PubMed ID: 2185316
[TBL] [Abstract][Full Text] [Related]
4. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
5. Resistance of human melanoma cells against the cytotoxic and complement-enhancing activities of doxorubicin.
Panneerselvam M; Bredehorst R; Vogel CW
Cancer Res; 1987 Sep; 47(17):4601-7. PubMed ID: 3621156
[TBL] [Abstract][Full Text] [Related]
6. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
7. A molecular mechanism of complement resistance of human melanoma cells.
Panneerselvam M; Welt S; Old LJ; Vogel CW
J Immunol; 1986 Apr; 136(7):2534-41. PubMed ID: 3081645
[TBL] [Abstract][Full Text] [Related]
8. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
9. Phylogeny of C4b-C3b cleaving activity: similar fragmentation patterns of human C4b and C3b produced by lower animals.
Kaidoh T; Gigli I
J Immunol; 1987 Jul; 139(1):194-201. PubMed ID: 3295051
[TBL] [Abstract][Full Text] [Related]
10. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
Ziccardi RJ
J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
[TBL] [Abstract][Full Text] [Related]
11. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
12. Role of the C3b-binding site on C4b-binding protein in regulating classical pathway C5 convertase.
Rawal N; Pangburn MK
Mol Immunol; 2007 Feb; 44(6):1105-14. PubMed ID: 16979240
[TBL] [Abstract][Full Text] [Related]
13. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of activation of the classical pathway of complement by monoclonal IgE (DES). Restricted regulation of C4b by C4b-binding protein.
Saint-Remy JM
Eur J Immunol; 1984 Mar; 14(3):254-9. PubMed ID: 6608450
[TBL] [Abstract][Full Text] [Related]
15. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
[TBL] [Abstract][Full Text] [Related]
16. A single arginine to tryptophan interchange at beta-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6. Implications for the location of a C5 binding site in C4.
Ebanks RO; Jaikaran AS; Carroll MC; Anderson MJ; Campbell RD; Isenman DE
J Immunol; 1992 May; 148(9):2803-11. PubMed ID: 1573269
[TBL] [Abstract][Full Text] [Related]
17. Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9.
Puentes SM; Da Silva RP; Sacks DL; Hammer CH; Joiner KA
J Immunol; 1990 Dec; 145(12):4311-6. PubMed ID: 2147941
[TBL] [Abstract][Full Text] [Related]
18. Ligand-binding renders the 160 kDa Trypanosoma cruzi complement regulatory protein susceptible to proteolytic cleavage.
Norris KA
Microb Pathog; 1996 Oct; 21(4):235-48. PubMed ID: 8905613
[TBL] [Abstract][Full Text] [Related]
19. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
[TBL] [Abstract][Full Text] [Related]
20. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
Medicus RG; Melamed J; Arnaout MA
Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
